compound semaglutide news FDA Warns Against Using Compounded Compound versions of GLP-1 drugs

This means dosage calculations depend on both the vial strength and dilution volume

You are exceeding clinical trial averages, likely through a combination of strong drug response and excellent lifestyle habits

the relevance to humans is uncertain and has not been confirmed in clinical studies

For instance, we neglected patient variability in their PK and PD response, though it is known that individual patients vary significantly in their weight loss outcomes from semaglutide 9 and tirzepatide

2~3 , , 2~3

If confirmed, the findings could add to a growing list of GLP-1 side effects that were not originally disclosed on the drug labels